Gerad H, Egorin M J, Whitacre M, Van Echo D A, Aisner J
Cancer Chemother Pharmacol. 1983;11(3):162-6. doi: 10.1007/BF00254197.
Three patients with advanced refractory malignancies were treated with whole-body hyperthermia (WBH: 42-42.3 degrees C) for 2 h during which time they also received an infusion of 60 or 80 mg/m2 of cis-diamminedichloroplatinum II (DDP). Each patient developed an elevated serum creatinine (2.7-13.6 mg/dl), with maximum creatinine occurring between days 7 and 12 after treatment. WBH did not alter plasma or urinary pharmacokinetics of total or ultrafilterable platinum compared with pharmacokinetic data of the same or other patients given DDP euthermically. Although the mechanism of the renal damage is unclear, it appears that WBH can potentiate the nephrotoxic actions of DDP and that further study of this combination is not warranted.
三名晚期难治性恶性肿瘤患者接受了全身热疗(WBH:42 - 42.3摄氏度),持续2小时,在此期间他们还接受了60或80mg/m²的顺二氯二氨铂II(DDP)输注。每位患者血清肌酐均升高(2.7 - 13.6mg/dl),肌酐最高值出现在治疗后第7至12天之间。与接受常温DDP的相同或其他患者的药代动力学数据相比,WBH并未改变总铂或超滤铂的血浆或尿液药代动力学。尽管肾损伤的机制尚不清楚,但似乎WBH可增强DDP的肾毒性作用,因此不值得对这种联合治疗进行进一步研究。